ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0060

Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0230

Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients with Inflammatory Bowel Disease – Clinical and MRI Findings from a Population-Based Cohort Study

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0235

Spine Structural Lesions in Ankylosing Spondylitis: Comparison Between Radiographic (RASSS) and Opportunistic Thoraco-abdomino-pelvic CT Assessment

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0063

Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0319

Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0071

Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0162

Statewide Burden of Low Back Pain in the United States and Its Trend from 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2022

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0611

Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0232

Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0603

Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0054

Supernatants from Macrophages Stimulated with Citrullinated and MAA-Modified Fibrinogen Contain PDGF-BB and TGF-b and Upregulate Fibrotic Markers in Human Lung Fibroblasts

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0160

Supplement Use in a Diverse Cohort of Individuals with SLE

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0202

Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0751

Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0592

Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

SpA Including PsA – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].